Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645242 · ClinicalTrials.gov registry record · Phase 3
A Study Of Diflucan In Children With Ringworm Of The Scalp
A Phase 3 study of Tinea Capitis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 185
- Enrollment target
- 20
- Study locations
NCT00645242 is a Phase 3 study of Tinea Capitis that has completed, run by Pfizer. The registered enrollment target is 185 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT00645242, a Phase 3 study of Tinea Capitis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 185 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of fluconazole for the treatment of tinea capitis in pediatric patients aged 3 to 12 years.
Conditions Studied
Interventions
- DRUG fluconazole
Study Locations (20)
Louisiana
- Pfizer Investigational Site - Gretna
- Pfizer Investigational Site - New Orleans
- Pfizer Investigational Site - Shreveport
Florida
- Pfizer Investigational Site - Miami
- Pfizer Investigational Site - Miami
Illinois
- Pfizer Investigational Site - Chicago
- Pfizer Investigational Site - Evanston
North Carolina
- Pfizer Investigational Site - Garner
- Pfizer Investigational Site - Raleigh
Ohio
- Pfizer Investigational Site - Cleveland
- Pfizer Investigational Site - Columbus
Alabama
- Pfizer Investigational Site - Montgomery
Arkansas
- Pfizer Investigational Site - Little Rock
California
- Pfizer Investigational Site - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2002-11 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00645242
The ClinicalTrials.gov registry entry for NCT00645242 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tinea Capitis appearing as the primary indexed condition, and to 1 intervention - of which fluconazole is the first listed.
NCT00645242 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Louisiana, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00645242 about?
NCT00645242 is a clinical study titled "A Study Of Diflucan In Children With Ringworm Of The Scalp". The purpose of this study is to evaluate the safety and efficacy of fluconazole for the treatment of tinea capitis in pediatric patients aged 3 to 12 years.
What is the current status of trial NCT00645242?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 2002-11. Estimated completion is 2003-03.
What conditions does trial NCT00645242 study?
This clinical trial studies the following conditions: Tinea Capitis.
What interventions are being tested in trial NCT00645242?
The interventions under investigation include: fluconazole (DRUG).
Who is sponsoring clinical trial NCT00645242?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00645242 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.